• We have just changed our forum software and are still tweaking things. You can log in using your existing user name and password. If you spot any problems please let us know by posting in the Feedback and suggestions section of the forum.

    Watch this short film to find out how to use the new forum!

Abilify (Aripriprazole) is a dopamine receptor partial agonist

T

Truthometer

Active member
Joined
Dec 20, 2016
Messages
35
#1


Aripriprazole (Abilify) is a partial agonist on 5HT1A, D2, D3, and D4 and an antagonist on 5HT2A. Abilify does not raise prolactin levels as a dopamine antagonist would cause. Abilify partially activates dopamine D2 receptors with intrinsic activity of up to 60% on postsynaptic receptors and 75% on presynaptic receptors, the activation of which cause the presynaptic neuron to release less dopamine [1] Abilify is has 68% intrinsic activity on 5HT1A receptors, activation of this receptor causes dopamine release in the prefrontal cortex.
 
Last edited:
T

Truthometer

Active member
Joined
Dec 20, 2016
Messages
35
#2
Abilify is a Partial Agonist

Abilify

D1 Antagonist
D2 Partial Agonist, 60%
D3 Partial Agonist
D4 Partial Agonist
D5 Antagonist
5HT1A Partial Agonist , 68%
5HT2A Antagonist
 
T

Truthometer

Active member
Joined
Dec 20, 2016
Messages
35
#3
On presynaptic D2 receptors, the intrinsic activity of Abilify gets as high as 75%. On postynaptic receptors it acts more like an antagonist, with intrinsic activity anywhere from 30%. Abilify acts as a dopamine partil agonist on the D2-like subfamily of dopamine receptors: D2, D3, and D4. Abilify is thought to inhibit dopamine transmission where it is in excess and promote dopaminergic transmission where it is deficit.

Abilify is a 5HT1A partial agonist with 68% intrinsic activity; which causes dopamine to be released in the prefrontal cortex, potentially treating depression, and negative symptoms of schizophrenia as well as cognitive deficits seen in this illness.

Abilify is a 5HT2A antagonist, which causes dopamine release in the nigrostriatal pathway.
This is a signature for atypical antipsychotics, as most of them block 5HT2A as well as dopamine D2.